COVID-19 and the pharma industry.

It’s a contentious relationship, but we all have our socially responsible part to play.

We’ve all been affected by the coronavirus pandemic, and while markets are down and social distancing is the new normal, the world looks to science to find a solution.

By partnering with a global #pharma company working towards the common antivirus goal, it’s possible to achieve great things, including:

★ Performing bioanalytical testing of blood samples from COVID-19 positive patients in record time

★ Implementing, developing & validating analytical methods for the testing of raw materials in readiness for mass-producing a COVID-19 vaccine on never-before-seen scale

★ Conducting bioequivalence studies with novel neuroprotective drugs which show significant anti-inflammatory properties

QUINTA-ANALYTICA have been quietly but successfully playing their part by utilizing specialist skill sets and equipment in-house to assist multiple partners in their quest to find a vaccine, or source APIs that have become as scarce as feathers on a fish!

Working with key research projects Quinta are proud to be doing their part in the collective effort to rid the world of the most impactful issue ever seen.

Additional News

  • 9 July 2025

    HER-096: A possible breakthrough in Parkinson’s disease treatment

    This testimonial highlights our collaboration with Herantis Pharma on the analytical development and nonclinical support for HER-096, a promising candidate in the fight against Parkinson’s disease.

  • 9 June 2025

    Ensuring Success in Buccal Film Development: The Midazolam Film Case Study

    Fast, Simple, Effective: Unlocking the Potential of Midazolam Films

  • 15 May 2025

    From Analytical Similarity to Clinical Data: Tailoring Evidence for Biosimilar Approval

    On behalf of Conscio Group, we are pleased to invite you to the upcoming free educational webinar.